In summary, this study provides essential preclinical evidence suggesting that EA reverses cognitive deficits and substantially lowers the burden of APP in AD model APP/PS1 mice, at least partially by inhibiting the JNK signaling pathway and regulating apoptosis signals (Yarza et al., 2016) (Figure 7). This evidence concerns the gene MAPK8 and Alzheimer disease.